Evidence map›Paper›PMID 32787942›Full record

ArticleBMC infectious diseases2020

Multidrug resistant and extensively drug resistant Acinetobacter baumannii hospital infection associated with high mortality: a retrospective study in the pediatric intensive care unit.

Jingyi Shi, Ting Sun, Yun Cui, Chunxia Wang, Fei Wang, Yiping Zhou, Huijie Miao, Yijun Shan, Yucai Zhang

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 78 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Synergy antibacterial effects of lytic phage vB_AbaA_LLY and levofloxacin against KL2 and KL160 Acinetobacter baumannii.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  6. Colistin Resistance inAntibiotics (Basel, Switzerland) · 2026
    Article
  7. Sulbactam-Durlobactam for Carbapenem-ResistantPathogens (Basel, Switzerland) · 2026
    Review
  8. Article
  9. Multidrug-resistantNew microbes and new infections · 2026
    Article
  10. Review
  11. Acute Post-cataract Surgery Endophthalmitis and Corneal Ulcer withJournal of research in pharmacy practice · 2026
    Article
  12. Article
  13. Prognostic Indicators of Carbapenem-ResistantHealth science reports · 2025
    Review
  14. Prevalence and Resistance Profiles ofAntibiotics (Basel, Switzerland) · 2025
    Review
  15. Article
  16. Clinical Analysis ofJournal of clinical medicine · 2025
    Article
  17. Article
  18. Article
  19. Article
  20. Phenotypical and Molecular Characterization ofLife (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jingyi ShiDepartment of Critical Care Medicine, Shanghai Children's Hospital, Shanghai Jiao Tong University, Shanghai, 20062, China.
Ting SunDepartment of Critical Care Medicine, Shanghai Children's Hospital, Shanghai Jiao Tong University, Shanghai, 20062, China.
Yun CuiDepartment of Critical Care Medicine, Shanghai Children's Hospital, Shanghai Jiao Tong University, Shanghai, 20062, China.
Chunxia WangDepartment of Critical Care Medicine, Shanghai Children's Hospital, Shanghai Jiao Tong University, Shanghai, 20062, China.
Fei WangDepartment of Critical Care Medicine, Shanghai Children's Hospital, Shanghai Jiao Tong University, Shanghai, 20062, China.
Yiping ZhouDepartment of Critical Care Medicine, Shanghai Children's Hospital, Shanghai Jiao Tong University, Shanghai, 20062, China.
Huijie MiaoDepartment of Critical Care Medicine, Shanghai Children's Hospital, Shanghai Jiao Tong University, Shanghai, 20062, China.
Yijun ShanDepartment of Critical Care Medicine, Shanghai Children's Hospital, Shanghai Jiao Tong University, Shanghai, 20062, China.
Yucai ZhangDepartment of Critical Care Medicine, Shanghai Children's Hospital, Shanghai Jiao Tong University, Shanghai, 20062, China. zyucai2018@163.com.ORCID http://orcid.org/0000-0002-4905-3600
Shanghai Jiao Tong University · CN

Funding

Science and Technology Commission of Shanghai Municipality 18411951000
6 · The paper itself

Abstract

backgroundMultidrug resistant (MDR) and extensively drug resistant (XDR) Acinetobacter baumannii presents challenges for clinical treatment and causes high mortality in children. We aimed to assess the risk factors and overall mortality for MDR/XDR Acinetobacter baumannii infected pediatric patients.

methodsThis retrospective study included 102 pediatric patients who developed MDR/XDR Acinetobacter baumannii infection in the pediatric intensive care unit (PICU) of Shanghai Children's Hospital in China from December 2014 to May 2018. Acinetobacter baumannii clinical isolates were recovered from different specimens including blood, sputum, bronchoalveolar lavage fluid, cerebrospinal fluid, ascites, hydrothorax, and urine. Antibiotic susceptibility test was determined according to the Clinical and Laboratory Standards Institute interpretive criteria. Clinical and biological data were obtained from the patients' medical records.

results102 patients with Acinetobacter baumannii infection were enrolled. The median age was 36 (9.6, 98.8) months, and there were 63 male in the case group. The overall mortality rate was 29.4%, while the Acinetobacter baumannii-associated mortality rate was 16.7% (17/102, 12 bloodstream infections, 4 meningitis and 1 intra-abdominal infection). Bloodstream infections occurred in 28 patients (27.5%), and 10 patients (9.8%) among them had central line-associated bloodstream infections (6 central venous catheters, 2 PICCs, 1 venous infusion port and 1 arterial catheter). Cerebrospinal fluid (CSF) cultures were positive in 4(3.9%) patients. 14(13.7%) patients got positive cultures in ascites and hydrothorax. Lower respiratory isolates (56/102) accounted for 54.9% of all patients. Non-survival patients appeared to have a lower NK cell activity (6.2% ± 3.61% vs. 9.15% ± 6.21%, P = 0.029), higher CD4+ T cell ratio (39.67% ± 12.18% vs. 32.66% ± 11.44%, P = 0.039),and a higher serum level of interlukin-8 (IL-8, 15.25 (1.62, 47.22)pg/mL vs. 0.1 (0.1, 22.99)pg/mL, P = 0.01) when Acinetobacter baumannii infection developed. Multivariate logistic analysis indicated that high serum level of Cr (RR, 0.934, 95%CI, 0.890-0.981; P = 0.007) and high BUN/ALB level (RR, 107.893, 95%CI, 1.425-870.574; p = 0.005) were associated with high risk of mortality in MDR/XDR Acinetobacter baumannii infected patients.

conclusionMDR/XDR Acinetobacter baumannii infection is a serious concern in pediatric patients with high mortality. Bloodstream and central nervous system infection accounted for high risk of death. Acute kidney injury is associated with high risk of mortality.

Indexed as

Intensive Care Units, PediatricAcinetobacter baumanniiAcinetobacter InfectionsAcute Kidney InjuryAnti-Bacterial AgentsBacteremiaCentral Nervous System InfectionsChildChild, PreschoolChinaCross InfectionDrug Resistance, Multiple, BacterialFemaleHospitalsHumansInfantAnti-Bacterial AgentsMDR/XDR, Acinetobacter baumanniiMortalityPediatric intensive care unitsRisk factors

Identifiers

PMID32787942
PMCPMC7422664
OpenAlexW3048495218

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.